Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China
Intellasia,
16-May-2022 Intellasia | PR Newswire Asia | 10:20 AM -Distribution channels in place to streamline/facilitate patient access.